Enzymological Characterization of <sup>64</sup>Cu-Labeled Neprilysin Substrates and Their Application for Modulating the Renal Clearance of Targeted Radiopharmaceuticals-Reference-Cited by-同舟云学术

Enzymological Characterization of ⁶⁴Cu-Labeled Neprilysin Substrates and Their Application for Modulating the Renal Clearance of Targeted Radiopharmaceuticals

Published:2023-01-03 Issue:1 Volume:66 Page:516-537
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Brandt Florian¹²,Ullrich Martin¹,Wodtke Johanna¹,Kopka Klaus¹²³⁴,Bachmann Michael¹³,Löser Reik¹²^ORCID,Pietzsch Jens¹²^ORCID,Pietzsch Hans-Jürgen¹²,Wodtke Robert¹^ORCID

Affiliation:

1. Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328Dresden, Germany

2. Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Mommsenstraße 4, 01069Dresden, Germany

3. National Center for Tumor Diseases (NCT) Dresden, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307Dresden, Germany

4. German Cancer Consortium (DKTK), Partner Site Dresden, Fetscherstraße 74, 01307Dresden, Germany

Funder

Deutsche Forschungsgemeinschaft

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01472

Reference93 articles.

1. 177Lu-PSMA Radioligand Therapy for Prostate Cancer

2. Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

3. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward

4. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

5. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with Al¹⁸F/⁶⁸Ga/¹¹¹In;Bioconjugate Chemistry;2024-08-26

2. FAP Radioligand Linker Optimization Improves Tumor Dose and Tumor-to-Healthy Organ Ratios in 4T1 Syngeneic Model;Journal of Medicinal Chemistry;2024-07-16

3. ⁶⁴Cu tumor labeling with hexadentate picolinic acid‐based bispidine immunoconjugates;Chemistry – A European Journal;2024-04-25

4. In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study;EJNMMI Research;2024-04-06

5. Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments;Theranostics;2024